Red
Brand Name(s):Remicade
Flixabi
Remsima
Inflectra
Zessly
Indication:Crohn’s Disease (moderate to severe) & long term maintenance of clinical remission and mucosal healing in ulcerative colitis in adults. Severe active ulcerative colitis or Crohn’s disease in children aged 6 to 17years.
Rationale:1,2,3,8
Considered:May-07
Review Date:Feb-24
Comments:
MHRA -Drug Safety Update
Tumour necrosis factor alpha inhibitors: risk of tuberculosis further information at:
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON404195
April 14